CUE BIOPHARMA INC. - COMMON STOCK

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

04 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

09 May 2024 15:05:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

08 May 2024 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference

07 May 2024 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 09:01:00 By Nasdaq GlobeNewswire

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

08 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

02 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

29 Feb 2024 09:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

22 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

09 Nov 2023 15:05:02 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

27 Sep 2023 08:05:00 By Nasdaq GlobeNewswire

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

26 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

09 Aug 2023 15:10:00 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

02 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting

14 Jun 2023 07:00:01 By Nasdaq GlobeNewswire